bipolar disorder

bipolar disorder
Name	Bipolar disorder
Field	Psychiatry
Symptoms	Mood swings, mania, depression, irritability
Complications	Suicide, occupational impairment, substance use disorders
Onset	Adolescence to early adulthood
Duration	Chronic
Types	Bipolar I disorder, Bipolar II disorder, Cyclothymia
Causes	Genetic, neurobiological, environmental
Diagnosis	Clinical assessment, mood charting
Treatment	Mood stabilizers, psychotherapy, electroconvulsive therapy
Frequency	~1–3% lifetime prevalence

bipolar disorder is a chronic affective condition characterized by recurrent episodes of elevated mood (mania or hypomania) and depressive episodes. It often causes marked impairment in social, occupational, and interpersonal functioning and is associated with increased risk of self-harm and comorbid medical conditions. The condition has been described and studied across clinical settings, psychiatric research centers, and population cohorts.

Signs and symptoms

Manic and hypomanic episodes manifest with elevated or irritable mood, increased energy, decreased need for sleep, pressured speech, grandiosity, impulsivity, and risky behavior, often prompting presentation to emergency departments, psychiatric inpatient units, or primary care clinics such as those associated with Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital. Depressive episodes involve low mood, anhedonia, psychomotor retardation, appetite changes, cognitive impairment, and suicidal ideation, generating referrals to services linked with NHS England, Veterans Health Administration, Kaiser Permanente, World Health Organization. Mixed features combine symptoms of mania and depression simultaneously, complicating treatment decisions used in protocols from American Psychiatric Association, Royal College of Psychiatrists, Canadian Psychiatric Association. Psychotic symptoms may occur during severe mood episodes, leading to interactions with specialty centers like McLean Hospital, Menninger Clinic, Sheppard Pratt Health System. Functionally, patients may experience disrupted work evaluated in studies at institutions such as Harvard Medical School, Stanford University School of Medicine, University of Oxford, University of Cambridge.

Causes and pathophysiology

Etiology reflects multifactorial influences including genetic liability demonstrated in family, twin, and genome-wide association studies carried out by consortia such as the Psychiatric Genomics Consortium, and cohorts from UK Biobank, Framingham Heart Study, Dunedin Multidisciplinary Health and Development Study. Neurobiological models implicate neurotransmitter systems studied at laboratories in National Institutes of Health, Max Planck Institute for Psychiatry, Karolinska Institutet; neural circuit dysfunction in prefrontal, limbic, and striatal regions reported in research from University College London, Yale University, Columbia University; and inflammatory and metabolic pathways explored by researchers at Scripps Research Institute, Johns Hopkins Bloomberg School of Public Health. Environmental exposures—perinatal complications, psychosocial stressors, and substance use—have been examined in longitudinal projects at Duke University, University of California, Los Angeles, McGill University. Pharmacogenomic and epigenetic mechanisms are subjects of investigation in collaborations with institutions such as Broad Institute, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory.

Diagnosis

Diagnosis relies on clinical assessment using structured interviews and diagnostic criteria from manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition and classifications maintained by World Health Organization via the International Classification of Diseases; standardized instruments include the Mood Disorder Questionnaire and Young Mania Rating Scale developed and validated in multicenter trials involving centers such as Stanford University School of Medicine, University of Toronto, King's College London. Differential diagnosis requires exclusion of substance-induced mood states and medical mimicry assessed in collaboration with specialties at Cleveland Clinic, Mayo Clinic, Mount Sinai Health System. Diagnostic challenges include distinguishing bipolar spectrum conditions from major depressive disorder in settings informed by guidelines from American Psychiatric Association, National Institute for Health and Care Excellence, Canadian Network for Mood and Anxiety Treatments.

Management and treatment

Evidence-based pharmacotherapy includes mood stabilizers and antipsychotics with regulatory approvals from agencies such as the U.S. Food and Drug Administration, European Medicines Agency, Health Canada; lithium, valproate, carbamazepine, and atypical antipsychotics are commonly used and monitored per protocols at centers like Vanderbilt University Medical Center, University of Pennsylvania Health System, University of California San Francisco Health. Psychotherapies—psychoeducation, cognitive behavioral therapy, family-focused therapy—are delivered in outpatient programs at institutions including McLean Hospital, Cambridge Health Alliance, Mount Sinai Hospital. Chronotherapeutic and neuromodulation approaches such as electroconvulsive therapy and transcranial magnetic stimulation are applied in specialist units at Beth Israel Deaconess Medical Center, Sheba Medical Center, Royal Melbourne Hospital. Management also involves relapse prevention, monitoring for metabolic adverse effects following recommendations from American Diabetes Association and collaboration with primary care networks like Geisinger Health System.

Prognosis and course

Course is episodic and heterogeneous: some individuals achieve long inter-episode remission while others experience rapid cycling or chronic subthreshold symptoms observed in longitudinal cohorts from Stanford University, Olmsted County, Minnesota studies, The National Institute of Mental Health Longitudinal Study of Bipolar Disorder. Risk of suicide and premature mortality is elevated and has been quantified in meta-analyses from research groups at University of Oxford, University of Manchester, King's College London. Functional recovery often lags symptomatic remission, necessitating vocational and psychosocial rehabilitation services provided by agencies such as National Alliance on Mental Illness, Mind (charity), Samaritans.

Epidemiology and history

Lifetime prevalence estimates vary across population surveys like those conducted by World Health Organization, National Comorbidity Survey, Global Burden of Disease Study, generally centering near 1–3% though broader spectrum definitions increase estimates. Age at onset typically occurs in adolescence or early adulthood, with clinical recognition and service delivery influenced by health systems including NHS Scotland, Medicare (Australia), Centers for Disease Control and Prevention. Historical descriptions date to clinical observations in the 19th century, with modern classification shaped by work at institutions such as Bethlem Royal Hospital, Salpêtrière Hospital, St. Luke's Hospital and conceptual advances disseminated through publications from Royal Society of Medicine and research funding by bodies such as National Institutes of Health and Medical Research Council.

Category:Mood disorders